- Home
- ARQT
as of 02-17-2026 3:46pm EST
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
| Founded: | 2016 | Country: | N/A |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 3.3B | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $11.75 - $31.77 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 86.38% | Revenue Growth (next year): | 30.29% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered ARQT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Arcutis Biotherapeutics Inc. (ARQT)
See Remarks
Avg Cost/Share
$25.81
Shares
9,794
Total Value
$252,747.88
Owned After
80,651
SEC Form 4
See Remarks
Avg Cost/Share
$25.33
Shares
40,638
Total Value
$1,027,292.65
Owned After
142,658
See Remarks
Avg Cost/Share
$25.50
Shares
3,675
Total Value
$93,706.62
Owned After
80,651
SEC Form 4
See Remarks
Avg Cost/Share
$25.50
Shares
19,833
Total Value
$505,709.77
Owned After
721,306
SEC Form 4
See Remarks
Avg Cost/Share
$25.50
Shares
2,052
Total Value
$52,322.72
Owned After
148,865
SEC Form 4
Director
Avg Cost/Share
$25.05
Shares
10,000
Total Value
$250,483.00
Owned After
59,744
SEC Form 4
SVP Chief Financial Officer
Avg Cost/Share
$25.50
Shares
1,320
Total Value
$33,657.89
Owned After
63,607
SEC Form 4
See Remarks
Avg Cost/Share
$28.98
Shares
2,490
Total Value
$72,165.68
Owned After
80,651
SEC Form 4
Director
Avg Cost/Share
$28.96
Shares
10,000
Total Value
$289,606.00
Owned After
59,744
SEC Form 4
See Remarks
Avg Cost/Share
$29.10
Shares
1,697
Total Value
$49,560.24
Owned After
80,651
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Burnett Patrick | ARQT | See Remarks | Feb 4, 2026 | Sell | $25.81 | 9,794 | $252,747.88 | 80,651 | |
| Matsuda Masaru | ARQT | See Remarks | Feb 2, 2026 | Sell | $25.33 | 40,638 | $1,027,292.65 | 142,658 | |
| Burnett Patrick | ARQT | See Remarks | Feb 2, 2026 | Sell | $25.50 | 3,675 | $93,706.62 | 80,651 | |
| Watanabe Todd Franklin | ARQT | See Remarks | Feb 2, 2026 | Sell | $25.50 | 19,833 | $505,709.77 | 721,306 | |
| Edwards Larry Todd | ARQT | See Remarks | Feb 2, 2026 | Sell | $25.50 | 2,052 | $52,322.72 | 148,865 | |
| Welgus Howard G. | ARQT | Director | Feb 2, 2026 | Sell | $25.05 | 10,000 | $250,483.00 | 59,744 | |
| Vairavan Latha | ARQT | SVP Chief Financial Officer | Feb 2, 2026 | Sell | $25.50 | 1,320 | $33,657.89 | 63,607 | |
| Burnett Patrick | ARQT | See Remarks | Jan 5, 2026 | Sell | $28.98 | 2,490 | $72,165.68 | 80,651 | |
| Welgus Howard G. | ARQT | Director | Jan 2, 2026 | Sell | $28.96 | 10,000 | $289,606.00 | 59,744 | |
| Burnett Patrick | ARQT | See Remarks | Dec 31, 2025 | Sell | $29.10 | 1,697 | $49,560.24 | 80,651 |
Compare ARQT vs Leading Stocks
See how ARQT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARQT Arcutis Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.